Media Articles Related to Zelnorm (Tegaserod)
Pioneering research advances treatment for overactive bladder and irritable bowel syndrome
Source: Irritable-Bowel Syndrome News From Medical News Today [2014.08.24]
Researchers at the University of Surrey have discovered how the receptors responsible for contractions in the bladder, regulate the body's clock genes.
Rifaximin (Xifaxan) for Irritable Bowel Syndrome (IBS) Treatment
Source: MedicineNet Constipation Specialty [2014.07.28]
Title: Rifaximin (Xifaxan) for Irritable Bowel Syndrome (IBS) Treatment
Category: Doctor's Views
Created: 1/18/2011 2:18:00 PM
Last Editorial Review: 7/28/2014 12:00:00 AM
Irritable Bowel Syndrome Triggers and Prevention
Source: MedicineNet Constipation Specialty [2014.07.23]
Title: Irritable Bowel Syndrome Triggers and Prevention
Category: Diseases and Conditions
Created: 5/12/2011 12:39:00 PM
Last Editorial Review: 7/23/2014 12:00:00 AM
Irritable Bowel Syndrome (IBS)
Source: MedicineNet alosetron Specialty [2014.02.28]
Title: Irritable Bowel Syndrome (IBS)
Category: Diseases and Conditions
Created: 2/25/2002 12:00:00 AM
Last Editorial Review: 2/28/2014 6:20:35 PM
IBS Pictures Slideshow: Understanding Irritable Bowel Syndrome
Source: MedicineNet Irritable Bowel Syndrome Specialty [2013.11.21]
Title: IBS Pictures Slideshow: Understanding Irritable Bowel Syndrome
Created: 2/12/2010 11:58:00 AM
Last Editorial Review: 11/21/2013 12:00:00 AM
Published Studies Related to Zelnorm (Tegaserod)
Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. [2011.02]
BACKGROUND: Abnormalities in gastric sensorimotor function (hypersensitivity to distention and impaired meal accommodation) have been implicated in the pathophysiology of functional dyspepsia (FD).In the subgroup with normal gastric emptying, tegaserod 6 mg b.i.d enhanced gastric accommodation.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. [2010.03]
BACKGROUND: Functional dyspepsia (FD) is a chronic disorder that adversely affects health-related quality of life (HRQoL). Published information on its long-term management is minimal and treatment options are limited. AIM: The aim of this study was to evaluate safety, efficacy and HRQoL with tegaserod 6 mg twice daily over 1 year in women with FD who completed one of two 6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was consistent with that of short-term treatment and accompanied by improvements in HRQoL, work productivity and symptom relief. These long-term results add to the clinical experience with FD and support the potential value of a 5-HT(4) agonist in the management of FD.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results
of two identical 1-year cohort studies. 
6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. [2008.08]
BACKGROUND: Problems of compliance, quality, and safety of colon preparation regimens have prompted continued investigation with alternative forms of cleansing. OBJECTIVE: To evaluate the efficacy of tegaserod as an adjunct to a polyethylene glycol electrolyte solution (PEG-E), given as a whole dose or split dose, in colonoscopy preparation... CONCLUSIONS: Tegaserod has a marginal effect on the quality of colonoscopy preparation when used as an adjuvant to PEG-E. The split-dose PEG-E was superior to the whole-dose PEG-E and resulted in better colon cleansing, adherence, and tolerance.
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. [2008.08]
OBJECTIVES: Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD... CONCLUSIONS: Some improvement in dysmotility-like FD was observed with tegaserod treatment. The clinical implication of this improvement is uncertain.
Clinical Trials Related to Zelnorm (Tegaserod)
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation [No longer available]
To provide tegaserod to eligible women adult patients who did not have satisfactory
improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic
constipation (CIC) symptoms with other available treatment(s) and / or patients who had
satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis [Terminated]
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis
treated with tegaserod over 2 weeks.
Safety and Efficacy of Tegaserod in Opioid-Induced Constipation in Patients With Non-Cancer Pain. [Terminated]
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation
(OIC) in patients with non-cancer pain.
Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis (IA)
receive the treatment as follows:
Patients on tegaserod 6 mg twice daily (b. i.d.) or 12 mg once daily (o. d.) in the core study
will remain on the same dose in the extension (double-blind).
Patients on placebo during the core study will receive tegaserod 12 mg o. d. (open-label)
Patients who enter this study AFTER the core study interim analysis will receive the selected
tegaserod dose regimen (open-label) determined by the core study IA.
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. [Completed]
The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia [Withdrawn]
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in
female patients with CC and upper GI symptoms of dyspepsia